Echo Therapeutics to Present at the 26th Annual ROTH Capital Conference

   Echo Therapeutics to Present at the 26th Annual ROTH Capital Conference

PR Newswire

PHILADELPHIA, March 3, 2014

PHILADELPHIA, March 3, 2014 /PRNewswire/ --Echo Therapeutics, Inc. (Nasdaq:
ECTE) ("Echo"), a medical device company developing its Symphony^® CGM System
as a non-invasive, wireless continuous glucose monitoring system, today
announced that Robert F. Doman, Executive Chairman and Interim CEO of Echo
Therapeutics, will present at the upcoming 26^th Annual ROTH Capital

Mr. Doman will make a corporate presentation to prospective corporate partners
and investors at 8:00 AM PT (11:00 AM ET) on Monday, March 10^th at the Ritz
Carlton, Dana Point, California.

At the time of the presentation, a live webcast of Mr. Doman's presentation
will be available in the Events section of the Company's website at Echo recommends registering at least 15 minutes prior to the
scheduled start time to ensure timely access. A replay will be available
following the presentation and accessible on for 30 days
following the event.

About Echo Therapeutics

Echo Therapeutics is developing the Symphony CGM System as a non-invasive,
wireless, continuous glucose monitoring system for use initially in the
critical care setting.A significant longer-term opportunity may also exist
for Symphony to be used in the hospital beyond the critical care setting, as
well as in patients with diabetes in the outpatient setting.Echo has also
developed its needle-free skin preparation device, the Prelude^® SkinPrep
System, as a platform technology to enhance delivery of topical

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts, including
the statement about the corporate presentation, may constitute forward-looking
statements that are based on current expectations and are subject to risks and
uncertainties that could cause actual future results to differ materially from
those expressed or implied by such statements. Those risks and uncertainties
include, but are not limited to, risks related to regulatory approvals and the
success of Echo's ongoing studies, including the safety and efficacy of Echo's
Symphony CGM System, the failure of future development and preliminary
marketing efforts related to Echo's Symphony CGM System, Echo's ability to
secure additional commercial partnering arrangements, risks and uncertainties
relating to Echo's and its partners' ability to develop, market and sell the
Symphony CGM System, the availability of substantial additional equity or debt
capital to support its research, development and product commercialization
activities, and the success of its research, development, regulatory approval,
marketing and distribution plans and strategies, including those plans and
strategies related to its Symphony CGM System. These and other risks and
uncertainties are identified and described in more detail in Echo's filings
with the Securities and Exchange Commission, including, without limitation,
its Annual Report on Form 10-K for the year ended December 31, 2012, its
Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo
undertakes no obligation to publicly update or revise any forward-looking

For More Information:
Christine H. Olimpio
Director, Investor Relations and Corporate Communications
(215) 717-4104

Connect With Us:
- Visit our website at
- Follow us on Twitter at
- Join us on Facebook at

SOURCE Echo Therapeutics, Inc.

Press spacebar to pause and continue. Press esc to stop.